Press Release

Late-phase therapeutic cancer vaccines to achieve lower sales of $1.3 billion by 2018

January 28th, 2010

Global Information would like to present a market research report, "Pipeline Insight: Therapeutic Cancer Vaccines Prospect of first approval set to reinvigorate interest from major companies" by Datamonitor.

High risk and uncertain rewards have limited larger companies involvement in the therapeutic cancer vaccines. Of the larger companies, GlaxoSmithKline and Merck KGaA have made the greatest commitment. The prospect of the first therapeutic vaccine approval in the US could stimulate renewed interest in this therapy class from further key players. Of the 13 vaccines in late-phase development, Provenge (Dendreon), Stimuvax (Merck KGaA/Oncothyreon) and MAGE-A3 ASCI (GlaxoSmithKline) have the highest clinical and commercial potential. Provenge is likely to be the first therapeutic cancer vaccine to market, having shown a statistically significant overall survival advantage in prostate cancer.

Scope of this research

  • Forecast sales of the therapeutic cancer vaccines in late-phase development in the seven major markets over the period 2009 to 2018
  • In-depth profiles and analysis for all vaccines in late-phase development, including trial data, SWOT analysis and clinical and commercial potential
  • Segmentation and analysis of the therapeutic cancer vaccine pipeline by developmental phase, class, indication and technology platform
  • Insight and analysis of market potential for therapeutic cancer vaccines including commercial opportunity, unmet needs and patient potential

Global Information Inc.(GII) - specializing in market research provision for the vertical industries, GII offers expert independent recommendations of publications from hundreds of the globe's leading market research firms.

Product Code : 105049